BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Zeprumetostat readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Zeprumetostat\, from ClinicalTrials.gov e
 stimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06568094-2727@assetmemo.bio
DTSTAMP:20261121T004530Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Zeprumetostat: Phase 1/2 readout est. (NCT06568094)
DESCRIPTION:Zeprumetostat\, phase 1/2.\nStudy: A Study of HRS-5041 Tablets 
 Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancer\
 nEstimated primary completion: December 2026. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/zeprumetostat#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT06568094
URL:https://assetmemo.bio/drug/zeprumetostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06519526-2727@assetmemo.bio
DTSTAMP:20261121T004530Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Zeprumetostat: Phase 2 readout est. (NCT06519526)
DESCRIPTION:Zeprumetostat\, phase 2\, Peripheral T-Cell Lymphoma.\nStudy: E
 xploratory Clinical Study of SHR-0302 and SHR-2554 in Patients With Relaps
 ed/Refractory Peripheral T Cell Lymphoma\nEstimated primary completion: 28
  February 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/zepru
 metostat#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06519526
URL:https://assetmemo.bio/drug/zeprumetostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06368167-2727@assetmemo.bio
DTSTAMP:20261121T004530Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Zeprumetostat: Phase 2 readout est. (NCT06368167)
DESCRIPTION:Zeprumetostat\, phase 2.\nStudy: A Phase II Study of SHR2554 in
  Patients With Relapsed or Refractory Follicular Lymphoma\nEstimated prima
 ry completion: April 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/zeprumetostat#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06368167
URL:https://assetmemo.bio/drug/zeprumetostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07294664-2727@assetmemo.bio
DTSTAMP:20261121T004530Z
DTSTART;VALUE=DATE:20270715
DTEND;VALUE=DATE:20270716
SUMMARY:Zeprumetostat: Phase 2 readout est. (NCT07294664)
DESCRIPTION:Zeprumetostat\, phase 2.\nStudy: PDL1/TGFβ In Combination With
  SHR2554 or Apatinib And Chemotherapy For First - Line Treatment Of Gastri
 c Cancer\nEstimated primary completion: 15 July 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/zeprumetostat#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07294664
URL:https://assetmemo.bio/drug/zeprumetostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07125950-2727@assetmemo.bio
DTSTAMP:20261121T004530Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Zeprumetostat: Phase 2 readout est. (NCT07125950)
DESCRIPTION:Zeprumetostat\, phase 2.\nStudy: SHR2554 Combined With Endocrin
 e Therapy in Advanced Breast Cancer\nEstimated primary completion: 30 Sept
 ember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/zeprumeto
 stat#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07125950
URL:https://assetmemo.bio/drug/zeprumetostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07102901-2727@assetmemo.bio
DTSTAMP:20261121T004530Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Zeprumetostat: Phase 2 readout est. (NCT07102901)
DESCRIPTION:Zeprumetostat\, phase 2.\nStudy: Safety and Efficacy of SHR2554
  Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal 
 Junction Adenocarcinoma\nEstimated primary completion: December 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/zeprumetostat#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07102901
URL:https://assetmemo.bio/drug/zeprumetostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07854639-2727@assetmemo.bio
DTSTAMP:20261121T004530Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Zeprumetostat: Phase 2 readout est. (NCT07854639)
DESCRIPTION:Zeprumetostat\, phase 2.\nStudy: A Prospective Clinical Study o
 f Zeprumetosta in Patients With Relapsed or Refractory Cutaneous T-Cell Ly
 mphoma\nEstimated primary completion: 1 December 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/zeprumetostat#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07854639
URL:https://assetmemo.bio/drug/zeprumetostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07502768-2727@assetmemo.bio
DTSTAMP:20261121T004530Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Zeprumetostat: Phase 1/2 readout est. (NCT07502768)
DESCRIPTION:Zeprumetostat\, phase 1/2.\nStudy: Tislelizumab Plus Zeprumetos
 tat for Relapsed or Refractory NK/T-Cell Lymphoma\nEstimated primary compl
 etion: 30 December 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/zeprumetostat#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07502768
URL:https://assetmemo.bio/drug/zeprumetostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07692529-2727@assetmemo.bio
DTSTAMP:20261121T004530Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Zeprumetostat: Phase 1 readout est. (NCT07692529)
DESCRIPTION:Zeprumetostat\, phase 1.\nStudy: A Clinical Study on the Effica
 cy and Safety of Zeprumetostat in Relapsed/Refractory Large Granular Lymph
 ocyte Leukemia\nEstimated primary completion: 31 December 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/zeprumetostat#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07692529
URL:https://assetmemo.bio/drug/zeprumetostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07706959-2727@assetmemo.bio
DTSTAMP:20261121T004530Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Zeprumetostat: Phase 1/2 readout est. (NCT07706959)
DESCRIPTION:Zeprumetostat\, phase 1/2\, Peripheral T-Cell Lymphoma.\nStudy:
  New Genotype-guided Treatment in Newly Diagnosed PTCL\nEstimated primary 
 completion: January 2028. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/zeprumetostat#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07706959
URL:https://assetmemo.bio/drug/zeprumetostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07339527-2727@assetmemo.bio
DTSTAMP:20261121T004530Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Zeprumetostat: Phase 1/2 readout est. (NCT07339527)
DESCRIPTION:Zeprumetostat\, phase 1/2.\nStudy: EZH2 Inhibitor Zeprumetostat
  in Combination Therapy for Patients With Relapsed or Refractory Mature T-
 cell and NK-cell Lymphomas\nEstimated primary completion: 1 January 2028. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/zeprumetostat#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07339527
URL:https://assetmemo.bio/drug/zeprumetostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07372352-2727@assetmemo.bio
DTSTAMP:20261121T004530Z
DTSTART;VALUE=DATE:20280115
DTEND;VALUE=DATE:20280116
SUMMARY:Zeprumetostat: Phase 2 readout est. (NCT07372352)
DESCRIPTION:Zeprumetostat\, phase 2.\nStudy: Zeprumetostat\, Azacitidine Co
 mbined With Lipo-MIT in R/R PTCL\nEstimated primary completion: 15 January
  2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/zeprumetostat#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0737
 2352
URL:https://assetmemo.bio/drug/zeprumetostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07717242-2727@assetmemo.bio
DTSTAMP:20261121T004530Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Zeprumetostat: Phase 2 readout est. (NCT07717242)
DESCRIPTION:Zeprumetostat\, phase 2.\nStudy: Sun Yat-Sen Treatment Strategy
  for Enhancing Response in Muscle-invasive Bladder Cancer\nEstimated prima
 ry completion: 30 June 2028. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/zeprumetostat#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07717242
URL:https://assetmemo.bio/drug/zeprumetostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07725705-2727@assetmemo.bio
DTSTAMP:20261121T004530Z
DTSTART;VALUE=DATE:20280801
DTEND;VALUE=DATE:20280802
SUMMARY:Zeprumetostat: Phase 1/2 readout est. (NCT07725705)
DESCRIPTION:Zeprumetostat\, phase 1/2\, Peripheral T-Cell Lymphoma.\nStudy:
  SHR2554 Plus Liposomal Mitoxantrone as First-line Treatment for Periphera
 l T-cell Lymphoma (PTCL)\nEstimated primary completion: 1 August 2028. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/zeprumetostat#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07725705
URL:https://assetmemo.bio/drug/zeprumetostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07175220-2727@assetmemo.bio
DTSTAMP:20261121T004530Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Zeprumetostat: Phase 2 readout est. (NCT07175220)
DESCRIPTION:Zeprumetostat\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: P
 hase II Clinical Study of SHR2554 Tablets Combined With Other Anti-tumor T
 reatments in Non-small Cell Lung Cancer Subjects\nEstimated primary comple
 tion: October 2028. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/z
 eprumetostat#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07175220
URL:https://assetmemo.bio/drug/zeprumetostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07230106-2727@assetmemo.bio
DTSTAMP:20261121T004530Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Zeprumetostat: Phase 2 readout est. (NCT07230106)
DESCRIPTION:Zeprumetostat\, phase 2.\nStudy: A Study of SHR3680\, HS-20093 
 and SHR2554 in Subjects With Prostate Cancer\nEstimated primary completion
 : December 2028. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/zepr
 umetostat#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07230106
URL:https://assetmemo.bio/drug/zeprumetostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07874425-2727@assetmemo.bio
DTSTAMP:20261121T004530Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Zeprumetostat: Phase 2 readout est. (NCT07874425)
DESCRIPTION:Zeprumetostat\, phase 2.\nStudy: Retlirafusp Alfa Combined With
  Zeprumetostat\, Apatinib\, and Chemotherapy as First-Line Treatment for M
 etastatic GC/GEJC\nEstimated primary completion: December 2028. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/zeprumetostat#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07874425
URL:https://assetmemo.bio/drug/zeprumetostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07347288-2727@assetmemo.bio
DTSTAMP:20261121T004530Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:Zeprumetostat: Phase 2 readout est. (NCT07347288)
DESCRIPTION:Zeprumetostat\, phase 2\, Peripheral T-Cell Lymphoma.\nStudy: S
 HR2554 as Maintenance Therapy in Patients With Peripheral T-cell Lymphoma\
 nEstimated primary completion: February 2029. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/zeprumetostat#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07347288
URL:https://assetmemo.bio/drug/zeprumetostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07575412-2727@assetmemo.bio
DTSTAMP:20261121T004530Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Zeprumetostat: Phase 2 readout est. (NCT07575412)
DESCRIPTION:Zeprumetostat\, phase 2.\nStudy: SHR2554/AZA + Overlapped Modif
 ied BUCY for High-risk/Relapsed Leukemia/MDS\nEstimated primary completion
 : June 2029. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/zeprumet
 ostat#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07575412
URL:https://assetmemo.bio/drug/zeprumetostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07493330-2727@assetmemo.bio
DTSTAMP:20261121T004530Z
DTSTART;VALUE=DATE:20291212
DTEND;VALUE=DATE:20291213
SUMMARY:Zeprumetostat: Phase 1/2 readout est. (NCT07493330)
DESCRIPTION:Zeprumetostat\, phase 1/2.\nStudy: Genotype-guided Targeted Age
 nts Plus EZH2i for Primary Refractory PTCL\nEstimated primary completion: 
 12 December 2029. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/zep
 rumetostat#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07493330
URL:https://assetmemo.bio/drug/zeprumetostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07555470-2727@assetmemo.bio
DTSTAMP:20261121T004530Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Zeprumetostat: Phase 2 readout est. (NCT07555470)
DESCRIPTION:Zeprumetostat\, phase 2.\nStudy: Mosunetuzumab and Zeprumetosta
 t in Treating Patients With Follicular Lymphoma\nEstimated primary complet
 ion: 31 December 2029. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/zeprumetostat#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07555470
URL:https://assetmemo.bio/drug/zeprumetostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07615283-2727@assetmemo.bio
DTSTAMP:20261121T004530Z
DTSTART;VALUE=DATE:20300529
DTEND;VALUE=DATE:20300530
SUMMARY:Zeprumetostat: Phase 1/2 readout est. (NCT07615283)
DESCRIPTION:Zeprumetostat\, phase 1/2\, Peripheral T-Cell Lymphoma.\nStudy:
  Adebrelimab Combined With SHR2554 in Relapsed/Refractory PTCL and NK/T-Ce
 ll Lymphoma\nEstimated primary completion: 29 May 2030. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/zeprumetostat#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07615283
URL:https://assetmemo.bio/drug/zeprumetostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07562568-2727@assetmemo.bio
DTSTAMP:20261121T004530Z
DTSTART;VALUE=DATE:20300630
DTEND;VALUE=DATE:20300701
SUMMARY:Zeprumetostat: Phase 2 readout est. (NCT07562568)
DESCRIPTION:Zeprumetostat\, phase 2.\nStudy: SHR2554/AZA + Overlapped TBF f
 or High-risk/Relapsed Leukemia/MDS\nEstimated primary completion: June 203
 0. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/zeprumetostat#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07562568
URL:https://assetmemo.bio/drug/zeprumetostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07724782-2727@assetmemo.bio
DTSTAMP:20261121T004530Z
DTSTART;VALUE=DATE:20300730
DTEND;VALUE=DATE:20300731
SUMMARY:Zeprumetostat: Phase 1/2 readout est. (NCT07724782)
DESCRIPTION:Zeprumetostat\, phase 1/2.\nStudy: Multi-Cohort Study of Zeprum
 etostat Combinations for Relapsed/Refractory PTCL\nEstimated primary compl
 etion: 30 July 2030. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 zeprumetostat#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07724782
URL:https://assetmemo.bio/drug/zeprumetostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07082803-2727@assetmemo.bio
DTSTAMP:20261121T004530Z
DTSTART;VALUE=DATE:20300930
DTEND;VALUE=DATE:20301001
SUMMARY:Zeprumetostat: Phase 1 readout est. (NCT07082803)
DESCRIPTION:Zeprumetostat\, phase 1.\nStudy: TLN-121 in Relapsed or Refract
 ory Non-Hodgkin Lymphomas\nEstimated primary completion: September 2030. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/zeprumetostat#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07082803
URL:https://assetmemo.bio/drug/zeprumetostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
